Abstracts Archive - Page 96 of 2425 - ACR Meeting Abstracts

Abstract Number: 0751 • ACR Convergence 2024
Sustained Drug-free Remission in Giant Cell Arteritis: Results Results of the Spanish ARTESER Registry
Javier Narvaez-García¹, Marta Domínguez-Álvaro², Eva Galíndez-Agirregoikoa³, Javier Mendizabal⁴, lydia Abasolo Alcazar⁵, Javier Loricera⁶, Noemí Garrido-Puñal⁷, Santos Castañeda⁸, Patricia Moya⁹, Carmen Larena¹⁰, Paula Estrada-Alarcón¹¹, Carlos Galisteo¹², Anne Riveros Frutos¹³, Francisco Ortiz Sanjuan¹⁴, Tarek Carlos Salman Monte:¹⁵, Margarida Vasques Rocha:¹⁶, Carlota Laura Iniguez Ubiaga¹⁷, Maria Garcia-Gonzalez¹⁸ and Ricardo Blanco-Alonso¹⁹, and ARTESER Project Collaborative Group, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Basurto, Bilbao, Spain, ⁴Complejo Hospitalario de Navarra, Pamplona, Spain, ⁵IdISSC. HCSC, Madrid, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁷Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹¹Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ¹²Hospital Universitario Parc Taulí, Sabadell, Spain, ¹³Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹⁴Hospital Universitario La Fe, Valencia, Spain, ¹⁵Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹⁶Hospital Universitario Araba, Vitoria, Spain, ¹⁷SERV. REUMATOLOGIA, Lugo, Spain, ¹⁸Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, ¹⁹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: To evaluate the frequency and timing of sustained drug-free remission (SDFR) in a Spanish cohort of patients with giant cell arteritis (GCA) and to…
Abstract Number: 0789 • ACR Convergence 2024
An Online Trial to Assess the Efficacy and Safety of a Supplement Combination in People with Hand Osteoarthritis
Xiaoqian Liu¹, Sarah Robbins¹, Jillian Eyles¹, Leticia Deveza¹, Andrew McLachlan¹ and David Hunter², ¹The University of Sydney, Sydney, New South Wales, Australia, ²Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia
Background/Purpose: Hand osteoarthritis is a debilitating and highly prevalent disease with limited treatment options. The aim of this study was to investigate the efficacy and…
Abstract Number: 0801 • ACR Convergence 2024
Neutrophil Activation as a Novel Marker of Lung Disease in Rheumatoid Arthritis
Jia Shi¹, Yang Wu¹, Ting Wang², Chen Yu³, qian wang⁴, Xinping Tian⁵, Mengtao Li⁴, Kristen Demoruelle⁶, Joshua Solomon⁷ and Christian Lood², ¹University of Washington, Seattle, ²University of Washington, Seattle, WA, ³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ⁴Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁶University of Colorado Anschutz Medical Campus, Golden, CO, ⁷National Jewish Health, Denver, CO
Background/Purpose: Neutrophil activation is seen in rheumatoid arthritis (RA), but its involvement in RA interstitial lung disease (RA-ILD) is not clear. Levels of N-formyl methionine…
Abstract Number: 0806 • ACR Convergence 2024
Rotavirus Vaccine in Offspring Exposed to Tumour Necrosis Factor Inhibitors During the Third Trimester Does Not Increase Diarrhea-Associated Healthcare Events
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St-Pierre⁴, Olga Basso¹, Anick Bérard⁵ and Evelyne Vinet³, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Université de Montréal, Montreal, QC, Canada
Background/Purpose: Until recently, best practice guidelines recommended withholding rotavirus vaccine in offspring exposed in utero to any TNFi until 6 months of age due to fears of…
Abstract Number: 0885 • ACR Convergence 2024
Reproducible Single Cell Annotation of Programs Underlying T-cell Subsets, Activation States, and Functions
Dylan Kotliar¹, Michelle Curtis¹, Ryan Agnew¹, Kathryn Weinand¹, Aparna Nathan², Yuriy Baglaenko¹, Yu Zhao¹, Pardis Sabeti³, Deepak Rao⁴ and Soumya Raychaudhuri¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Broad Institute, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Background/Purpose: T-cells play a key role in the pathogenesis of autoimmune disease and in protection against cancer and infection. Consequently, there is widespread interest in…
Abstract Number: 0845 • ACR Convergence 2024
Weight Loss, Disease Activity, and Patient Reported Outcomes in Patients with Musculoskeletal and Autoimmune Diseases Taking Weight Loss Therapies
Thomas Riley¹, Kristin Wipfler², Katherine Wysham³, Michael George⁴, Kaleb Michaud⁵ and Joshua Baker⁴, ¹Hopsital of the University of Pennsylvania, Philadelphia, PA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: With the popularity of medication-assisted weight loss, the current study seeks to characterize the association of weight loss, disease activity, and patient reported outcomes…
Abstract Number: 0754 • ACR Convergence 2024
Clinical Characterization of Aortitis and Periaortitis in a Cohort of 134 Patients from a Single Universitary Center. A Model-based Cluster Analysis
Carmen Secada Gómez¹, Javier Loricera², Adrián Martín-Gutiérrez³, Fernando Lopez-Gutierrez⁴, María Nuñez-Sayar⁵, Ander Ucelay-Aristi⁵, Isabel Martinez-Rodriguez⁶, ivan Ferraz-Amaro⁷, Santos Castañeda⁸ and Ricardo Blanco-Alonso⁹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ⁵Cardiovascular Surgery, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁶Nuclear Medicine, Hospital Universitario Marques de Valdecilla,IDIVAL, Santander, Cantabria, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Aortitis and periaortitis represent the inflammation of the aortic wall and the surrounding periaortic tissues, respectively. Both can be idiopathic or secondary to infectious…
Abstract Number: 0877 • ACR Convergence 2024
Zasocitinib (TAK-279) Displays High Levels of TYK2 Inhibition and No Inhibition of JAK 1/3 Compared with Licensed TYK2 and JAK Inhibitors
Shailly Mehrotra¹, Yasuyo Sano¹, Elizabeth Wilson¹, Chandrasekar Durairaj², Kok-Fai Kong¹, Guliang Xia³, Faith Dunbar³, Taylor Spector¹, Christopher Bunick⁴ and Iain McInnes⁵, ¹Takeda Development Center Americas, Inc., Cambridge, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Takeda Development Center Americas, Inc, Cambridge, ⁴Yale University School of Medicine, New Haven, ⁵University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom
Background/Purpose: Zasocitinib (TAK-279), an oral, allosteric, selective, tyrosine kinase 2 (TYK2) inhibitor in late-stage clinical development for the treatment of immune-mediated inflammatory diseases including psoriatic…
Abstract Number: 0808 • ACR Convergence 2024
Confirmation of Second Trimester Trophoblast Transport of Maternal Anti-SSA/Ro52 and 60kD Autoantibodies in Cardiac Neonatal Lupus: Implications for FcRn Blockade
Nicola Fraser¹, Mala Masson², Robert Clancy³, Philip Carlucci⁴, Peter Izmirly⁵, Nalani Sachan⁶, Justin Brandt¹, Kristen Thomas¹, Melanie Fox⁷, Colin Phoon¹, Achiau Ludomirsky¹, Ranjini Srinivasan¹, Garrett Lam⁸, Bettina Cuneo⁹ and Jill Buyon¹⁰, ¹NYU Langone Health, New York, NY, ²NYU Langone Medical Center- Division of Rheumatology, New York, NY, ³Columbia University Medical Center, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵New York University Grossman School of Medicine, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Renown Health, Reno, NV, ⁸Intermountain Health, Provo, UT, ⁹University of Arizona College of Medicine, Tucson, AZ, ¹⁰New York University Grossman School of Medicine, New York, NY
Background/Purpose: The nearly invariant finding of anti-SSA/Ro52/60kD autoantibodies in pregnancies complicated by cardiac neonatal lupus (cardiac-NL), which manifests as fetal atrioventricular block and endocardial fibroelastosis…
Abstract Number: 0849 • ACR Convergence 2024
Effectiveness of Tocilizumab in Aortitis and Aneurysms Associated with Giant Cell Arteritis. Multicenter Open-label Study
Adrián Martín-Gutiérrez¹, Javier Loricera², Carmen Secada Gómez³, Iñigo Hernández-Rodríguez⁴, Susana Romero Yuste⁵, Eugenio De Miguel⁶, Eva Galindez-Agirregoikoa⁷, ivan Ferraz-Amaro⁸, Julio Sánchez-Martín⁹, Patricia Moya Albarado¹⁰, Cristina Campos Fernández¹¹, Fernando Lopez-Gutierrez¹², Santos Castañeda¹³ and Ricardo Blanco-Alonso¹⁴, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁵Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁸Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁰Hospital de San Pau, Barcelona, Spain, ¹¹Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ¹²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Giant Cell Arteritis (GCA) was initially described involving mainly the extracranial branches of the carotid arteries. However, GCA also may involve the aorta (GCA-aortitis)…
Abstract Number: 0864 • ACR Convergence 2024
Obesity Subtypes and Trajectories of Functional Change After 7-years of Follow-up: The Multicenter Osteoarthritis (MOST) Study
Kristine Godziuk¹, Sarah Tilley², mike LaValley³, Michael Nevitt⁴, C.E. Lewis⁵, James Torner⁶ and Tuhina Neogi², ¹University of Alberta, Edmonton, AB, Canada, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴UCSF, Orinda, CA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Iowa, Iowa City
Background/Purpose: People with knee osteoarthritis (OA) and obesity (i.e. BMI ≥30kg/m2) have poorer function than those without obesity. However, function is not uniform among people…
Abstract Number: 0863 • ACR Convergence 2024
The Development of Future Radiographic Knee Osteoarthritis Can Be Predicted by Peripheral Blood Epigenetic Models
Cindy Miranda¹, Nicholas Hannebutt², Gabby dyson³, Montana Barrett⁴, Aleksander Szymczak³ and Matlock Jeffries³, ¹Oklahoma Medical Research Foundation, Yukon, OK, ²Oklahoma Medical Research Foundation, Spencer, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴University of Oklahoma, Cement, OK
Background/Purpose: Knee osteoarthritis (OA) is a heterogeneous disease characterized by a variety of clinical and molecular phenotypes. However, we do not yet have robust biomarkers…
Abstract Number: 0764 • ACR Convergence 2024
Primary Treatment Failure to Tocilizumab in Giant Cell Arteritis
Paul Cioni¹, Hubert de Boysson², Simon Parreau³, Perrine SMETS⁴, Maxime SAMSON⁵, Sara Melboucy⁶, Herve Lobbes⁷, Nabil Belfeki⁸, François Perrin⁹, Pascal Maurice Rossi¹⁰, Eric Liozon¹¹, Guillaume Le Guenno¹², Claire Le Jeunne¹, OLIVIER FOGEL¹³, Lola Prat¹⁴, Florent Ladouce¹⁵, Sylvie Grosleron¹⁶, Halil Yildiz¹⁷, Vincent Grosbost¹⁵, Xavier Puéchal¹⁸, Chloe Comarmond¹⁹ and Benjamin Terrier²⁰, ¹Cochin University Hospital, Paris, France, ²Caen university Hospital, Caen, France, ³Dupuytren hospital, Limoges, France, ⁴Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ⁵Dijon University Hospital, Dijon, France, ⁶CH Saint Quentin, Saint Quentin, France, ⁷CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁸GHSIF - Melun, Melun, France, ⁹CH Saint Nazaire, Saint Nazaire, France, ¹⁰CHU Hopital Nord Marseille, Marseille, France, ¹¹CHU Limoges, Limoges, France, ¹²CHU, Clermont-Ferrand, France,, Clermont-Ferrand, France, ¹³AP-HP, Paris, France, ¹⁴Jacques Cartier Hospital, Massy, France, ¹⁵Clermont Ferrand University Hospital, Clermont Ferrand, France, ¹⁶CH Agen-Nerac, Agen, France, ¹⁷Saint-Luc University Clinic, Bruxells, Belgium, ¹⁸National Referral Center For Rare Systemic Autoimmune Diseases, Paris, France, ¹⁹Lariboisière University Hospital, Paris, France, ²⁰Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Giant cell arteritis (GCA) is the most common vasculitis in people over the age of 50. Glucocorticoids are the cornerstone of treatment for GCA,…
Abstract Number: 0883 • ACR Convergence 2024
The Study of 62 Circulating Soluble Factors Is Able to Predict the Lack of Response to MTX Treatment in Recently Diagnosed DMARD Naïve Rheumatoid Arthritis Smoker and Non-Smoker Patients
Jorge Monserrat¹, Cristina Bohorquez², Ana Maria Gómez³, Elena Rabadán Rubio⁴, Raquel Sánchez³, Atusa Movasat⁵, Lucia Ruiz⁴, Fernando Albarran Hernandez⁶, Miguel Ángel Ortega¹, Ana Perez⁶ and Melchor Alvarez-Mon⁷, ¹Universidad de Alcalá. IRYCIS, Alcalá de Henares, Madrid, Spain, ²Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain, ³Universidad de Alcalá, Alcalá de Henares, Madrid, Spain, ⁴Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, ⁵Hospital Universitario Príncipe de Asturias, Madrid, Spain, ⁶Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, ⁷Universidad de Alcalá. HUPA. IRYCIS, Madrid, Spain

Background/Purpose: Rheumatoid arthritis (RA) is a highly inflammatory severe chronic autoimmune disorder with an inadequate activation of the immune cells. These cells are responsible for…
Abstract Number: 0870 • ACR Convergence 2024
The Impact of Body Mass Index on Cardiovascular Risk in Rheumatoid Arthritis Varies Across Anticitrullinated Protein Antibody Status and Biologic Use
George Karpouzas¹, Elena Myasoedova², Miguel Angel Gonzalez-Gay³, alfonso Corrales-Martínez⁴, Solbritt Rantapaa-Dahlqvist⁵, Petros Sfikakis⁶, Patrick Dessein⁷, Linda Tsang⁸, Carol Hitchon⁹, Hani El Gabalawy¹⁰, Virginia Pascual Ramos¹¹, Irazu Contreras Yanez¹², Iris Jazmín Colunga Pedraza¹³, Dionicio Galarza-Delgado¹⁴, jose Ramon Azpiri-Lopez¹⁵, Anne Grete Semb¹⁶, Piet Van RIel¹⁷, Durga P Misra¹⁸, Patrick Durez¹⁹, Brian Bridal Logstrup²⁰, Ellen Margrethe Hauge²¹, George Kitas²² and Sarah Ormseth²³, and An inTernationAl Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA), ¹Harbor-UCLA Medical Center and the Lundquist Institute, Torrance, CA, ²Mayo Clinic, Rochester, MN, ³University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁵Umeå University, Umeå, Sweden, ⁶Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁷University of Witwatersrand, Johannesburg, South Africa, ⁸University of Witwatersrand, Johanessburg, South Africa, ⁹University of Mannitoba, Winnipeg, Canada, ¹⁰University of Mannitoba, Winnipeg, MB, Canada, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ¹²Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ¹⁵Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁶Diakonhjemmet Hospital, Oslo, Norway, ¹⁷Radboud University Medical Center, Nijmegen, Netherlands, ¹⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁹UCLouvain, Louvain, Belgium, ²⁰University of Aarhus, Aarhus, Denmark, ²¹Aarhus Universitetshospital, Aarhus, Denmark, ²²The Dudley Group NHS, Birmingham, United Kingdom, ²³The Lundquist Institute, Torrance, CA
Background/Purpose: The impact of body mass index (BMI) as a surrogate of body fat content on cardiovascular (CV) risk in rheumatoid arthritis (RA) is unclear.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].